Determination of fVIII antigen, fVIII activity, and anti-fVIII Abs in 25 inhibitor-negative hemophilia A subjects
| Disease severity and subject ID . | fVIII antigen, pM . | fVIII activity, pM (%) . | fVIII Ab, nM . |
|---|---|---|---|
| Severe hemophilia | |||
| 1* | ND | 7.9 (1.1) | ND |
| 1†‡ | ND | NA | ND |
| 2* | 14.3 ± 3.3 | 11.6 (1.7) | 5.2 ± 0 |
| 2†‡ | 7.9 ± 2.0 | 25.1 (3.6) | 5.7 ± 0.5 |
| 3*‡ | 19.8 ± 5.9 | 67.9 (9.7) | ND |
| 4*‡ | 134.8 ± 10.7 | 49.4 (7.1) | ND |
| 5*‡ | 57.7 ± 5.5 | 103.7 (14.8) | ND |
| 6*‡ | 47.7 ± 1.4 | 93.3 (13.3) | ND |
| 7*‡ | 67.4 ± 4.8 | 97 (13.9) | ND |
| 8*‡ | 2.8 ± 1.1 | 9.3 (1.3) | 3.2 ± 0.3 |
| 9*‡ | 9.8 ± 0.9 | 17.3 (2.5) | ND |
| 10*‡ | ND | 32.3 (4.6) | ND |
| 11*‡ | 0.9 ± 0.7 | 18.5 (2.7) | ND |
| Moderate hemophilia | |||
| 12* | 40.1 ± 3.3 | 28.7 (4.1) | ND |
| 12† | 19.8 ± 1.4 | 24.5 (3.5) | 0.6 ± 0.4 |
| 13* | 18.5 ± 3.3 | 55.7 (8) | ND |
| 13† | 20.9 ± 1.4 | 48.7 (7) | ND |
| 14* | 43.3 ± 2.6 | 65.2 (9.3) | ND |
| 14† | ND | 29.5 (4.2) | ND |
| 15* | 1.6 ± 1.3 | 26.2 (3.7) | ND |
| 15† | 3.5 ± 1.4 | 20.3 (2.9) | ND |
| Mild hemophilia | |||
| 16* | ND | 103.7 (14.8) | ND |
| 16† | ND | NA | ND |
| 17* | 17.2 ± 5.9 | NA | ND |
| 17† | 20.6 ± 1.1 | NA | ND |
| 18* | 68 ± 2.6 | 35.5 (5.1) | 20.0 ± 4.0 |
| 18† | 35.9 ± 2.6 | 41.0 (5.9) | 18.9 ± 1.5 |
| 19* | 28.8 ± 3.7 | 36.4 (5.2) | ND |
| 19†‡ | 35.2 ± 0.5 | 35.9 (5.1) | 10.1 ± 6.9 |
| 20* | 63.8 ± 0.3 | 97 (13.9) | 1.3 ± 0.4 |
| 20† | 81.1 ± 2.6 | 126.5 (18.1) | 1.1 ± 0.3 |
| 21* | 132.4 ± 5.2 | 173.7 (24.8) | ND |
| 21† | 167 ± 3.9 | 98.3 (14.1) | ND |
| 22* | 50.4 ± 4.4 | 9.3 (1.3) | ND |
| 22† | 61.8 ± 0.7 | 97 (13.9) | ND |
| 23* | 30.2 ± 0.9 | 62.7 (9) | ND |
| 23† | 39.8 ± 3.7 | 93.3 (13.3) | ND |
| 24* | 137.5 ± 20.6 | NA | ND |
| 25* | 155.6 ± 5.2 | 54.9 (7.9) | ND |
| Disease severity and subject ID . | fVIII antigen, pM . | fVIII activity, pM (%) . | fVIII Ab, nM . |
|---|---|---|---|
| Severe hemophilia | |||
| 1* | ND | 7.9 (1.1) | ND |
| 1†‡ | ND | NA | ND |
| 2* | 14.3 ± 3.3 | 11.6 (1.7) | 5.2 ± 0 |
| 2†‡ | 7.9 ± 2.0 | 25.1 (3.6) | 5.7 ± 0.5 |
| 3*‡ | 19.8 ± 5.9 | 67.9 (9.7) | ND |
| 4*‡ | 134.8 ± 10.7 | 49.4 (7.1) | ND |
| 5*‡ | 57.7 ± 5.5 | 103.7 (14.8) | ND |
| 6*‡ | 47.7 ± 1.4 | 93.3 (13.3) | ND |
| 7*‡ | 67.4 ± 4.8 | 97 (13.9) | ND |
| 8*‡ | 2.8 ± 1.1 | 9.3 (1.3) | 3.2 ± 0.3 |
| 9*‡ | 9.8 ± 0.9 | 17.3 (2.5) | ND |
| 10*‡ | ND | 32.3 (4.6) | ND |
| 11*‡ | 0.9 ± 0.7 | 18.5 (2.7) | ND |
| Moderate hemophilia | |||
| 12* | 40.1 ± 3.3 | 28.7 (4.1) | ND |
| 12† | 19.8 ± 1.4 | 24.5 (3.5) | 0.6 ± 0.4 |
| 13* | 18.5 ± 3.3 | 55.7 (8) | ND |
| 13† | 20.9 ± 1.4 | 48.7 (7) | ND |
| 14* | 43.3 ± 2.6 | 65.2 (9.3) | ND |
| 14† | ND | 29.5 (4.2) | ND |
| 15* | 1.6 ± 1.3 | 26.2 (3.7) | ND |
| 15† | 3.5 ± 1.4 | 20.3 (2.9) | ND |
| Mild hemophilia | |||
| 16* | ND | 103.7 (14.8) | ND |
| 16† | ND | NA | ND |
| 17* | 17.2 ± 5.9 | NA | ND |
| 17† | 20.6 ± 1.1 | NA | ND |
| 18* | 68 ± 2.6 | 35.5 (5.1) | 20.0 ± 4.0 |
| 18† | 35.9 ± 2.6 | 41.0 (5.9) | 18.9 ± 1.5 |
| 19* | 28.8 ± 3.7 | 36.4 (5.2) | ND |
| 19†‡ | 35.2 ± 0.5 | 35.9 (5.1) | 10.1 ± 6.9 |
| 20* | 63.8 ± 0.3 | 97 (13.9) | 1.3 ± 0.4 |
| 20† | 81.1 ± 2.6 | 126.5 (18.1) | 1.1 ± 0.3 |
| 21* | 132.4 ± 5.2 | 173.7 (24.8) | ND |
| 21† | 167 ± 3.9 | 98.3 (14.1) | ND |
| 22* | 50.4 ± 4.4 | 9.3 (1.3) | ND |
| 22† | 61.8 ± 0.7 | 97 (13.9) | ND |
| 23* | 30.2 ± 0.9 | 62.7 (9) | ND |
| 23† | 39.8 ± 3.7 | 93.3 (13.3) | ND |
| 24* | 137.5 ± 20.6 | NA | ND |
| 25* | 155.6 ± 5.2 | 54.9 (7.9) | ND |